Identification of thioredoxin-interacting protein (TXNIP) as a downstream target for IGF1 action

Karthik Nagaraj, Lena Lapkina-Gendler, Rive Sarfstein, David Gurwitz, Metsada Pasmanik-Chor, Zvi Laron, Shoshana Yakar, Haim Werner

Research output: Contribution to journalArticle

Abstract

Laron syndrome (LS), or primary growth hormone (GH) insensitivity, is the best-characterized entity among the congenital insulin-like growth factor 1 (IGF1) deficiencies. Life-long exposure to minute endogenous IGF1 levels is linked to low stature as well as a number of endocrine and metabolic abnormalities. While elevated IGF1 is correlated with increased cancer incidence, epidemiological studies revealed that patients with LS do not develop tumors. The mechanisms associated with cancer protection in LS are yet to be discovered. Recent genomic analyses identified a series of metabolic genes that are overrepresented in patients with LS. Given the augmented expression of these genes in a low IGF1 milieu, we hypothesized that they may constitute targets for IGF1 action. Thioredoxin-interacting protein (TXNIP) plays a critical role in cellular redox control by thioredoxin. TXNIP serves as a glucose and oxidative stress sensor, being commonly silenced by genetic or epigenetic events in cancer cells. Consistent with its enhanced expression in LS, we provide evidence that TXNIP gene expression is negatively regulated by IGF1. These results were corroborated in animal studies. In addition, we show that oxidative and glucose stresses led to marked increases in TXNIP expression. Supplementation of IGF1 attenuated TXNIP levels, suggesting that IGF1 exerts its antiapoptotic effect via inhibition of TXNIP. Augmented TXNIP expression in LS may account for cancer protection in this condition. Finally, TXNIP levels could be potentially useful in the clinic as a predictive or diagnostic biomarker for IGF1R-targeted therapies.

Original languageEnglish (US)
Pages (from-to)1045-1050
Number of pages6
JournalProceedings of the National Academy of Sciences of the United States of America
Volume115
Issue number5
DOIs
StatePublished - Jan 30 2018

Fingerprint

Thioredoxins
Somatomedins
Laron Syndrome
Proteins
Neoplasms
Oxidative Stress
Gene Expression
Glucose
Epigenomics
Growth Hormone
Oxidation-Reduction
Epidemiologic Studies
Cohort Studies
Biomarkers

Keywords

  • IGF1 receptor
  • Insulin-like growth factor 1
  • Laron syndrome
  • TXNIP

ASJC Scopus subject areas

  • General

Cite this

Identification of thioredoxin-interacting protein (TXNIP) as a downstream target for IGF1 action. / Nagaraj, Karthik; Lapkina-Gendler, Lena; Sarfstein, Rive; Gurwitz, David; Pasmanik-Chor, Metsada; Laron, Zvi; Yakar, Shoshana; Werner, Haim.

In: Proceedings of the National Academy of Sciences of the United States of America, Vol. 115, No. 5, 30.01.2018, p. 1045-1050.

Research output: Contribution to journalArticle

Nagaraj, Karthik ; Lapkina-Gendler, Lena ; Sarfstein, Rive ; Gurwitz, David ; Pasmanik-Chor, Metsada ; Laron, Zvi ; Yakar, Shoshana ; Werner, Haim. / Identification of thioredoxin-interacting protein (TXNIP) as a downstream target for IGF1 action. In: Proceedings of the National Academy of Sciences of the United States of America. 2018 ; Vol. 115, No. 5. pp. 1045-1050.
@article{d828346f9d46407d8ecd65a796c5505f,
title = "Identification of thioredoxin-interacting protein (TXNIP) as a downstream target for IGF1 action",
abstract = "Laron syndrome (LS), or primary growth hormone (GH) insensitivity, is the best-characterized entity among the congenital insulin-like growth factor 1 (IGF1) deficiencies. Life-long exposure to minute endogenous IGF1 levels is linked to low stature as well as a number of endocrine and metabolic abnormalities. While elevated IGF1 is correlated with increased cancer incidence, epidemiological studies revealed that patients with LS do not develop tumors. The mechanisms associated with cancer protection in LS are yet to be discovered. Recent genomic analyses identified a series of metabolic genes that are overrepresented in patients with LS. Given the augmented expression of these genes in a low IGF1 milieu, we hypothesized that they may constitute targets for IGF1 action. Thioredoxin-interacting protein (TXNIP) plays a critical role in cellular redox control by thioredoxin. TXNIP serves as a glucose and oxidative stress sensor, being commonly silenced by genetic or epigenetic events in cancer cells. Consistent with its enhanced expression in LS, we provide evidence that TXNIP gene expression is negatively regulated by IGF1. These results were corroborated in animal studies. In addition, we show that oxidative and glucose stresses led to marked increases in TXNIP expression. Supplementation of IGF1 attenuated TXNIP levels, suggesting that IGF1 exerts its antiapoptotic effect via inhibition of TXNIP. Augmented TXNIP expression in LS may account for cancer protection in this condition. Finally, TXNIP levels could be potentially useful in the clinic as a predictive or diagnostic biomarker for IGF1R-targeted therapies.",
keywords = "IGF1 receptor, Insulin-like growth factor 1, Laron syndrome, TXNIP",
author = "Karthik Nagaraj and Lena Lapkina-Gendler and Rive Sarfstein and David Gurwitz and Metsada Pasmanik-Chor and Zvi Laron and Shoshana Yakar and Haim Werner",
year = "2018",
month = "1",
day = "30",
doi = "10.1073/pnas.1715930115",
language = "English (US)",
volume = "115",
pages = "1045--1050",
journal = "Proceedings of the National Academy of Sciences of the United States of America",
issn = "0027-8424",
number = "5",

}

TY - JOUR

T1 - Identification of thioredoxin-interacting protein (TXNIP) as a downstream target for IGF1 action

AU - Nagaraj, Karthik

AU - Lapkina-Gendler, Lena

AU - Sarfstein, Rive

AU - Gurwitz, David

AU - Pasmanik-Chor, Metsada

AU - Laron, Zvi

AU - Yakar, Shoshana

AU - Werner, Haim

PY - 2018/1/30

Y1 - 2018/1/30

N2 - Laron syndrome (LS), or primary growth hormone (GH) insensitivity, is the best-characterized entity among the congenital insulin-like growth factor 1 (IGF1) deficiencies. Life-long exposure to minute endogenous IGF1 levels is linked to low stature as well as a number of endocrine and metabolic abnormalities. While elevated IGF1 is correlated with increased cancer incidence, epidemiological studies revealed that patients with LS do not develop tumors. The mechanisms associated with cancer protection in LS are yet to be discovered. Recent genomic analyses identified a series of metabolic genes that are overrepresented in patients with LS. Given the augmented expression of these genes in a low IGF1 milieu, we hypothesized that they may constitute targets for IGF1 action. Thioredoxin-interacting protein (TXNIP) plays a critical role in cellular redox control by thioredoxin. TXNIP serves as a glucose and oxidative stress sensor, being commonly silenced by genetic or epigenetic events in cancer cells. Consistent with its enhanced expression in LS, we provide evidence that TXNIP gene expression is negatively regulated by IGF1. These results were corroborated in animal studies. In addition, we show that oxidative and glucose stresses led to marked increases in TXNIP expression. Supplementation of IGF1 attenuated TXNIP levels, suggesting that IGF1 exerts its antiapoptotic effect via inhibition of TXNIP. Augmented TXNIP expression in LS may account for cancer protection in this condition. Finally, TXNIP levels could be potentially useful in the clinic as a predictive or diagnostic biomarker for IGF1R-targeted therapies.

AB - Laron syndrome (LS), or primary growth hormone (GH) insensitivity, is the best-characterized entity among the congenital insulin-like growth factor 1 (IGF1) deficiencies. Life-long exposure to minute endogenous IGF1 levels is linked to low stature as well as a number of endocrine and metabolic abnormalities. While elevated IGF1 is correlated with increased cancer incidence, epidemiological studies revealed that patients with LS do not develop tumors. The mechanisms associated with cancer protection in LS are yet to be discovered. Recent genomic analyses identified a series of metabolic genes that are overrepresented in patients with LS. Given the augmented expression of these genes in a low IGF1 milieu, we hypothesized that they may constitute targets for IGF1 action. Thioredoxin-interacting protein (TXNIP) plays a critical role in cellular redox control by thioredoxin. TXNIP serves as a glucose and oxidative stress sensor, being commonly silenced by genetic or epigenetic events in cancer cells. Consistent with its enhanced expression in LS, we provide evidence that TXNIP gene expression is negatively regulated by IGF1. These results were corroborated in animal studies. In addition, we show that oxidative and glucose stresses led to marked increases in TXNIP expression. Supplementation of IGF1 attenuated TXNIP levels, suggesting that IGF1 exerts its antiapoptotic effect via inhibition of TXNIP. Augmented TXNIP expression in LS may account for cancer protection in this condition. Finally, TXNIP levels could be potentially useful in the clinic as a predictive or diagnostic biomarker for IGF1R-targeted therapies.

KW - IGF1 receptor

KW - Insulin-like growth factor 1

KW - Laron syndrome

KW - TXNIP

UR - http://www.scopus.com/inward/record.url?scp=85041182676&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85041182676&partnerID=8YFLogxK

U2 - 10.1073/pnas.1715930115

DO - 10.1073/pnas.1715930115

M3 - Article

C2 - 29339473

AN - SCOPUS:85041182676

VL - 115

SP - 1045

EP - 1050

JO - Proceedings of the National Academy of Sciences of the United States of America

JF - Proceedings of the National Academy of Sciences of the United States of America

SN - 0027-8424

IS - 5

ER -